AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Nucleotide-binding oligomerization domain-containing protein 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9HC29

UPID:

NOD2_HUMAN

Alternative names:

Caspase recruitment domain-containing protein 15; Inflammatory bowel disease protein 1

Alternative UPACC:

Q9HC29; E2JEQ6; Q96RH5; Q96RH6; Q96RH8

Background:

Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) is a critical pattern recognition receptor (PRR) that plays a pivotal role in gastrointestinal immunity. It detects bacterial peptidoglycan fragments, activating immune responses. NOD2's interaction with various signaling molecules triggers pathways essential for maintaining intestinal microbiota balance and controlling inflammation.

Therapeutic significance:

NOD2's involvement in Blau syndrome, Inflammatory bowel disease 1, and Yao syndrome highlights its therapeutic significance. Understanding NOD2's role could lead to innovative treatments for these conditions, emphasizing the importance of targeting this protein in drug discovery efforts.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.